Fibroblast growth factors and their inhibitors.
Fibroblast growth factors (FGFs) are members of a family of polypeptides synthesized by a variety of cell types during the processes of embryonic development and in adult tissues. FGFs have been detected in normal and malignant cells and show a biological profile that includes mitogenic and angiogenic activity with a consequent crucial role in cell differentiation and development. To activate signal transduction pathways, FGFs use a dual receptor system based on tyrosine kinases and heparan sulfate (HS) proteoglycans. Based on these considerations, a variety of inhibitors able to block the interactions between FGFs and their receptors have been designed and investigated for their biological properties related to antiangiogenesis and antitumor activity. In this paper, in addition to an extensive description of the FGF family members, we report several compounds acting as FGF inhibitors by direct interaction with the growth factors. Suramin and other diverse polyanionic polysulfated and polysulfonated compounds are described, with a particular focus on suradistas. For this class of molecules, by means of molecular modeling procedures, a binding model to FGF-2 has been proposed and the structure-activity relationships of suradistas have been analyzed on the basis of the computational model described.
Botta
M
M
Dipartimento Farmaco Chimico Tecnologico, Universita degli Studi di Siena, Via Aldo Moro snc, Siena, 53100, Italy.
Manetti
F
F
Corelli
F
F
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001846:Bone Development; D005260:Female; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology*; D006801:Humans; D008958:Models, Molecular; D018919:Neovascularization, Physiologic; D006080:Ovarian Follicle / Q000502:physiology; D013329:Structure-Activity Relationship; D013498:Suramin / Q000031:analogs & derivatives / Q000494:pharmacology; D009626:Terminology as Topic
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D013498:Suramin; D005346:Fibroblast Growth Factors